The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
The company is making its entry into the Hyderabad market through its unique asset-light business model
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
The acquisition is for an enterprise value of Rs. 218 crores
Subscribe To Our Newsletter & Stay Updated
